DRG Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of ADHD for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology’s ADHD forecast will answer the following questions:

  • Of all people with ADHD, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with ADHD, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ADHD over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, DRG Epidemiology forecasts the following 13 ADHD patient populations:

  • Prevalent cases of pediatric ADHD by DSM-IV criteria.
  • Prevalent cases of pediatric ADHD by diagnosis status.
  • Diagnosed prevalent cases of pediatric ADHD by drug-treatment status.
  • Prevalent cases of pediatric ADHD by comorbid oppositional defiant disorder (ODD).
  • Prevalent cases of pediatric ADHD by subtype.
  • Prevalent cases of pediatric ADHD by symptoms.
  • Prevalent cases of adult ADHD by DSM-IV criteria.
  • Prevalent cases of adult ADHD by diagnosis status.
  • Diagnosed prevalent cases of adult ADHD by drug-treatment status.
  • Prevalent cases of adult ADHD by subtype.
  • Total prevalent cases of ADHD by DSM-5 criteria.
  • Total incident cases of ADHD by DSM-5 criteria.
  • Lifetime disability-adjusted life years (DALYs) gained.
  • … and more (details available on request).

Note: Coverage may vary by country.

Table of contents

  • Attention-Deficit-Hyperactivity Disorder - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Total Prevalence of ADHD per 100 People Aged 0-19 in 2019 and 2039
      • Total Prevalence of Adult ADHD per 100 People Aged 20+ in 2019 and 2039
      • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Pediatric ADHD over the Next 20 Years
      • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Adult ADHD over the Next 20 Years
      • Analysis of the Total Prevalent Cases of Pediatric ADHD by Diagnosed and Drug-Treated Status
      • Analysis of the Total Prevalent Cases of Adult ADHD by Diagnosed and Drug-Treated Status
      • Analysis of the Total Prevalent Cases of Pediatric ADHD in 2019 by Subtype
      • Analysis of the Total Prevalent Cases of Adult ADHD in 2019 by Subtype
    • Epidemiology Data
    • Methods
      • True Incident Cases
      • Lifetime DALYs Gained
      • Total Prevalent Cases of ADHD Based on the DSM-IV
      • Total Prevalent Cases of Pediatric ADHD Symptoms
      • Total Prevalent Cases of ADHD Based on the DSM-5
      • Total Prevalent Cases of ADHD by Subtype
      • Total Prevalent Cases of Pediatric ADHD with Comorbid ODD
      • Diagnosed Prevalent Cases of ADHD
      • Drug-Treated Cases of ADHD
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of ADHD
        • Studies Excluded from the Analysis of ADHD
      • Risk/Protective Factors
        • Risk/Protective Factors for ADHD
      • Bibliography

Author(s): Mudasir Khan, M.P.H.; Abey John, MPH

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.